Workflow
Earnings estimate
icon
Search documents
WK Kellogg (KLG) Soars 7.0%: Is Further Upside Left in the Stock?
ZACKS· 2025-07-02 11:21
Group 1: WK Kellogg Company Overview - WK Kellogg (KLG) shares increased by 7% to close at $17.05, supported by strong trading volume, contrasting with a 0.3% loss over the past four weeks [1] - The rise in shares is attributed to optimism regarding the company's strategic transformation, including cost-reduction efforts, brand revitalization, and enhanced pricing power [1] - The company's focus on improving margins and stabilizing volumes is boosting investor confidence [1] Group 2: Earnings Expectations - WK Kellogg is expected to report quarterly earnings of $0.38 per share, reflecting a year-over-year increase of 5.6%, while revenues are projected to be $657.22 million, a decrease of 2.2% from the previous year [2] - The consensus EPS estimate for WK Kellogg has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Group 3: Industry Context - WK Kellogg holds a Zacks Rank of 3 (Hold) within the Consumer Products - Staples industry [4] - BRC Inc. (BRCC), another company in the same industry, saw a 15.3% increase in its stock price, closing at $1.51, despite a -23.4% return over the past month [4] - BRC Inc.'s consensus EPS estimate has remained unchanged at -$0.03, representing a 200% decline compared to the previous year's EPS, and it currently holds a Zacks Rank of 5 (Strong Sell) [5]
Constellation Brands (STZ) Q1 Earnings and Revenues Lag Estimates
ZACKS· 2025-07-01 22:15
Financial Performance - Constellation Brands reported quarterly earnings of $3.22 per share, missing the Zacks Consensus Estimate of $3.34 per share, and down from $3.57 per share a year ago, representing an earnings surprise of -3.59% [1] - The company posted revenues of $2.52 billion for the quarter ended May 2025, missing the Zacks Consensus Estimate by 2.07%, and down from $2.66 billion year-over-year [2] - Over the last four quarters, Constellation Brands has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Performance - Constellation Brands shares have lost approximately 26.4% since the beginning of the year, contrasting with the S&P 500's gain of 5.5% [3] - The current status of estimate revisions translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $4.07 on revenues of $2.68 billion, and for the current fiscal year, it is $12.68 on revenues of $9.44 billion [7] - The outlook for the Beverages - Alcohol industry is positive, currently ranking in the top 32% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]
Ameris Bancorp (ABCB) Upgraded to Buy: Here's What You Should Know
ZACKS· 2025-07-01 17:01
Ameris Bancorp (ABCB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Indi ...
Agco (AGCO) Upgraded to Buy: Here's Why
ZACKS· 2025-07-01 17:01
Group 1 - Agco (AGCO) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which significantly influences stock prices [1][3] - The Zacks rating system is based on changes in earnings estimates, which are tracked through a consensus measure from sell-side analysts [1][2] - The upgrade reflects an improvement in Agco's underlying business, suggesting that investors may respond positively by driving the stock price higher [5][10] Group 2 - The correlation between earnings estimate revisions and stock price movements is strong, with institutional investors using these estimates to determine fair value [4][6] - For the fiscal year ending December 2025, Agco is expected to earn $4.20 per share, with a 1.2% increase in the Zacks Consensus Estimate over the past three months [8] - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7][9] Group 3 - The placement of Agco in the top 20% of Zacks-covered stocks indicates its strong earnings estimate revision feature, suggesting potential for market-beating returns in the near term [10]
Customers Bancorp (CUBI) Upgraded to Buy: Here's What You Should Know
ZACKS· 2025-07-01 17:01
Customers Bancorp (CUBI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The ...
Bilibili (BILI) Upgraded to Strong Buy: What Does It Mean for the Stock?
ZACKS· 2025-07-01 17:01
Bilibili (BILI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power ...
Coca-Cola (KO) Upgraded to Buy: Here's Why
ZACKS· 2025-07-01 17:01
Coca-Cola (KO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Since a changing earnin ...
Advanced Energy (AEIS) Upgraded to Buy: Here's What You Should Know
ZACKS· 2025-07-01 17:01
Core Viewpoint - Advanced Energy Industries (AEIS) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is solely based on a company's changing earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - The Zacks rating upgrade for Advanced Energy reflects an improvement in its earnings outlook, which is expected to positively impact its stock price [4][6]. Impact of Earnings Estimate Revisions - Changes in a company's future earnings potential, as shown by earnings estimate revisions, are strongly correlated with near-term stock price movements [5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to significant price movements based on their investment actions [5]. Advanced Energy's Earnings Outlook - Advanced Energy is projected to earn $5.16 per share for the fiscal year ending December 2025, with no year-over-year change expected [9]. - Over the past three months, the Zacks Consensus Estimate for Advanced Energy has increased by 4.6%, indicating a positive trend in earnings estimates [9]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [8]. - The upgrade of Advanced Energy to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10][11].
What Makes SBA Communications (SBAC) a New Buy Stock
ZACKS· 2025-07-01 17:01
Core Viewpoint - SBA Communications (SBAC) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine a company's fair value, leading to significant stock price movements based on these estimates [4]. Business Improvement Indicators - The upgrade in SBA Communications' rating reflects an improvement in the company's underlying business, suggesting that investors may respond positively by driving the stock price higher [5][10]. - Over the past three months, the Zacks Consensus Estimate for SBA Communications has increased by 1%, with expected earnings of $12.74 per share for the fiscal year ending December 2025, unchanged from the previous year [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - The upgrade of SBA Communications to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
ZACKS· 2025-07-01 15:31
Core Insights - Immunome, Inc. (IMNM) shares increased by 6% to close at $9.3, driven by higher trading volume compared to typical sessions, contrasting with a 0.1% gain over the past four weeks [1][2] Company Performance - The rise in stock price is linked to growing investor optimism regarding the development of varegacestat, which is in late-stage clinical studies for treating desmoid tumors, alongside other early-stage cancer therapies [2] - The company is projected to report a quarterly loss of $0.52 per share, reflecting a year-over-year decline of 6.1%, with expected revenues of $2.47 million, an increase of 4.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has been revised 1.9% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] Industry Context - Immunome is categorized under the Zacks Medical - Biomedical and Genetics industry, where Nurix Therapeutics, Inc. (NRIX) also operates, closing 2.2% lower at $11.39, with a 9.5% return over the past month [5] - Nurix Therapeutics has an unchanged consensus EPS estimate of -$0.72 for the upcoming report, representing a year-over-year change of -1.4% [6]